Biotech Fight Fears of ‘Antibiotic Apocalypse’
Kevin Outterson is quoted in Financial Times.
New Campaign Focuses on Fighting Superbugs
Kevin Outterson is mentioned in Cision
$1.6 Million Dollars Awarded to Develop Staphylococcus Aureus Bacteria Vaccine
Kevin Outterson and CARB-X are featured in Vax Before Travel.
CARB-X Partnership Pushes Development of New Antibiotics
Kevin Outterson is interviewed in KSL.com.
Our Antibiotics Are Becoming Useless
Kevin Outterson quoted in Vox.
CARB-X Launches New Funding Rounds To Support the Development of Antibiotics, Vaccines, Diagnostics and Other Life-Saving Products That Target Drug-Resistant Bacteria
(BOSTON, MA) – CARB-X announced today its 2019 rounds of funding to support the development of antibiotics, vaccines, biotherapeutics, diagnostics and other life-saving products to address the rising threat of drug-resistant bacteria. There are four funding rounds representing CARB-X’s most ambitious call for proposals from product developers seeking financial, scientific and business support to accelerate […]
Specific Diagnostics Achieves CARB-X Milestone and Advances Its Reveal Rapid Antibiotic Susceptibility Test For Life-Threatening Drug-Resistant Infections
BU Law featured in “Specific Diagnostics Achieves CARB-X Milestone and Advances Its Reveal Rapid Antibiotic Susceptibility Test For Life-Threatening Drug-Resistant Infections,” Benzinga.
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens
CARB-X featured in Nasdaq.
Kean University Joins Global Network to Combat Antibiotic-Resistant Superbugs
BU Law featured in NJBIZ.
CARB-X to Fund Antibiotic Development Initiative
Kevin Outterson featured in Homeland Preparedness News.